Item 1.01 Entry into a Material Definitive Agreement.
Securities Purchase Agreement
On February 26, 2018, Jaguar Health, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agreement) with Chicago Venture Partners, L.P. (CVP), pursuant to which the Company issued to CVP a promissory note (the Note) in the aggregate principal amount of $2,240,909 for an aggregate purchase price of $1,560,000. The Note carries an original issue discount of $655,909, and the initial principal balance also includes $25,000 to cover CVPs transaction expenses. The Company will use the proceeds for general corporate purposes and working capital. The Note bears interest at the rate of 8% per annum and matures on (i) August 26, 2019 if the Company has raised at least $12 million in equity after the issuance date of the Note (the Redemption Start Condition) and on or before April 1, 2018 or (ii) November 26, 2018 if the Redemption Start Condition is not satisfied on or before April 1, 2018.
Under the Securities Purchase Agreement, the Company is subject to certain covenants, including the obligations of the Company to: (i) timely file all reports required to be filed under Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) and not terminate its status as an issuer required to file reports under the Exchange Act; (ii) maintain listing of the Companys common stock on a securities exchange; (iii) avoid trading in the Companys common stock from being suspended, halted, chilled, frozen or otherwise ceased; (iv) not issue any variable securities (i.e., Company securities that (a) have conversion rights of any kind in which the number of shares that may be issued pursuant to the conversion right varies with the market price of the Companys common stock or (b) are or may become convertible into shares of the Companys common stock with a conversion price that varies with the market price of such stock) that generate gross cash proceeds to the Company of less than the lesser of $1 million and the then-current outstanding balance of the Note without CVPs prior consent; (v) not grant a security interest in its assets without CVPs prior consent; (vi) not issue any shares of common stock to certain institutional investors; (vii) repay the Hercules Loan (as defined below) within one month of the closing of the Note issuance; (viii) not incur any debt other than in the ordinary course of business, and in no event greater than $10,0000, without CVPs prior consent; and (ix) other customary covenants and obligations, for which the Companys failure to comply may be subject to certain liquidated damages.
In addition, beginning on the Redemption Start Date (as defined below), the Company has the right to redeem all or any portion of the outstanding balance of the Note in cash or as otherwise mutually agreed upon between the parties. The Redemption Start Date is the date that is (i) seven months from the effective date of the Note (the Effective Date) if the Redemption Start Condition is satisfied by April 1, 2018 or (ii) six months from the Effective Date if (x) the Redemption Start Condition is not satisfied by April 1, 2018 or (y) at any time after the Effective Date CVP breaches any of the covenants set forth in the Securities Purchase Agreement.
If the Redemption Start Condition is satisfied by April 1, 2018, the Company and CVP also agree to amend that certain Secured Convertible Promissory Note in the original amount of $2,155,000 issued by Company in favor of CVP on June 29, 2017 (the June 2017 Note) and that certain Secured Promissory Note in the original amount of $1,587,500 issued by Company in favor of CVP on December 8, 2017 (the December 2017 Note, and together with the June 2017 Note, the Prior Notes) to (i) extend the maturity date of the Prior Notes to August 26, 2019, (ii) postpone the date on which CVP can exercise its right to redeem the Prior Notes to September 26, 2018 and (iii) limit the aggregate amount that CVP is permitted to redeem on a monthly basis to $500,000, which amount is the maximum aggregate redemption amount for the Prior Notes and the Note collectively.
The Note was offered and sold pursuant to an exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
The Securities Purchase Agreement and the other transaction documents and obligations of the Company thereunder are subject in all respects to the terms of that certain subordination agreement and right to purchase debt (the Subordination Agreement) that the Company entered into with CVP with Hercules Capital, Inc. (Hercules) on June 29, 2017, pursuant to which (i) CVP subordinated (a) all of the Companys debt and obligations to CVP to all of the Companys indebtedness and obligations to Hercules and (b) all of CVPs security interest, if any, in the Companys assets to all of Hercules security interest in the Companys assets and (ii) Hercules granted CVP the right to purchase 100% of the debt under the Companys term loan so long as the purchase includes the full pay-out of funds owed to Hercules under the term loan at such time.
Security Agreement
The Company also entered into a security agreement (the Security Agreement) with CVP, pursuant to which CVP will receive a security interest in substantially all of the Companys assets. The security interest is effective upon CVPs purchase of the Companys outstanding obligations under that certain loan and security agreement, dated August 18, 2015, between the Company and Hercules Capital, Inc. (as amended, the Hercules Loan) or upon such time that the Hercules Loan is otherwise repaid in full.
2